ACE2 alternatively converts angiotensin (Ang) II into Ang-(1–7) and Ang I into Ang-(1–9). There is little information in the literature with respect to Ang-(1–9) properties. A number of studies show a link between peptides of the renin-angiotensin system and thrombosis.
Materials and methods:
We have investigated the influence of Ang-(1–9) on stasis-induced venous thrombosis in the rat. The contribution of coagulation and fibrinolytic systems, angiotensin receptor type 1 (AT1) and MAS receptor in the mode of Ang-(1–9) action was also determined.
Results:
Ang-(1–9) enhanced thrombosis development, decreased plasma concentration of tissue plasminogen activator and increased the level of its inhibitor (PAI-1). The action of Ang-(1–9) was reversed by selective antagonist of AT1 receptor, but not Ang-(1–7) antagonist. Ang-(1–9) did not bind to the AT1 receptor.
Conclusions:
Ang-(1–9) enhances venous thrombosis in the rat because of the impairment of fibrinolysis. The prothrombotic effect of Ang-(1–9) is mediated by Ang II acting via the AT1 receptor.
MogielnickiAChabielskaEPawlakR. Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost2005; 93: 1069–1076.
2.
DonoghueMHsiehFBaronasE. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res2000; 87: E1–E9.
3.
TipnisSRHooperNMHydeR. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem2000; 275: 33238–33243.
4.
SnyderRAWintroubBU. Inhibition of angiotensin-converting enzyme by des-Leu10-angiotensin I: A potential mechanism of endogenous angiotensin-converting enzyme regulation. Biochim Biophys Acta1986; 871: 1–5.
5.
SnyderRAWattKWWintroubBU. A human platelet angiotensin I-processing system. Identification of components and inhibition of angiotensin-converting enzyme by product. J Biol Chem1985; 260: 7857–7860.
6.
KokkonenJOSaarinenJKovanenPT. Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1–9) formed by heart carboxypeptidase A-like activity. Circulation1997; 95: 1455–1463.
7.
LawrenceACEvinGKladisA. An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal-directed antisera: Measurement of eight angiotensin peptides in human plasma. J Hypertens1990; 8: 715–724.
8.
JohnsonHKourtisSWatersJ. Radioimmunoassay for immunoreactive [des-Leu10]-angiotensin. Peptides1989; 10: 489–492.
9.
CampbellDJLawrenceACTowrieA. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension1991; 18: 763–773.
10.
OcaranzaMPGodoyIJalilJE. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension2006; 48: 572–578.
11.
OcaranzaMPLavanderoSJalilJE. Angiotensin-(1–9) regulates cardiac hypertrophy in vivo and in vitro. J Hypertens2010; 28: 1054–1064.
12.
Flores-MuñozMWorkLMDouglasK. Angiotensin-(1–9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. Hypertension2012; 59: 300–307.
KramkowskiKMogielnickiALeszczynskaA. Angiotensin-(1–9), the product of angiotensin I conversion in platelets, enhances arterial thrombosis in rats. J Physiol Pharmacol2010; 61: 317–324.
KucharewiczIPawlakRMatysT. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1–7). Hypertension2002; 40: 774–779.
19.
JackmanHLMassadMGSekosanM. Angiotensin 1–9 and 1–7 release in human heart: Role of cathepsin A. Hypertension2002; 39: 976–981.
20.
LeMTDe BackerJPHunyadyL. Ligand binding and functional properties of human angiotensin AT1 receptors in transiently and stably expressed CHO-K1 cells. Eur J Pharmacol2005; 513: 35–45.
21.
PawlakRChabielskaEGolatowskiJ. Nitric oxide and prostacyclin are involved in antithrombotic action of captopril in venous thrombosis in rats. Thromb Haemost1998; 79: 1208–1212.
22.
ChabielskaEPawlakRWollnyT. Antithrombotic activity of losartan in two kidney, one clip hypertensive rats. A study on the mechanism of action. J Physiol Pharmacol1999; 50: 99–109.
23.
DingYAMacIntyreDEKenyonCJ. Potentiation of adrenaline-induced platelet aggregation by angiotensin II. Thromb Haemost1985; 54: 717–720.
24.
NishimuraHTsujiHMasudaH. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost1997; 77: 1189–1195.
25.
Flores-MuñozMSmithNJHaggertyC. Angiotensin1–9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. J Physiol2011; 589: 939–951.
26.
SinghRSinghAKLeeheyDJ. A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol2005; 288: F1183–F1190.
27.
WakefieldTWMyersDDHenkePK. Mechanisms of venous thrombosis and resolution. Arterioscler Thromb Vasc Biol2008; 28: 387–391.
28.
van LeeuwenRTKolAAndreottiF. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation1994; 90: 362–368.
